Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Curr Hematol Malig Rep. 2018 Oct;13(5):383–395. doi: 10.1007/s11899-018-0471-9

Fig. 1.

Fig. 1

Immunograms of baseline and dynamic biomarkers. Examples of immunograms, including available baseline and dynamic biomarkers, potentially associated with response or lack of response to immune checkpoint blockade (ICB). Systematic assessment of biomarker immunograms before and after treatment in correlation with outcome will help define the tumor-immune state(s) and type of evolution that predict a clinical response